Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient must be diagnosed with any of the approved epilepsy indications for CBZ that include: Partial seizures with complex symptomatology (psychomotor, temporal lobe); Generalized tonic clonic seizures (grand mal); Mixed seizure patterns that include one of the above; Other partial or generalized seizures.~* Patient must be receiving a stable dose of oral CBZ (tablet or capsule formulation) for a minimum of 14 days prior to Day -28.~* Patient must be receiving a constant dose of all other concomitant medications / device (including AEDs, Vagal Nerve Stimulator (VNS), OTC medications, and herbal supplements) that may not interfere with the metabolism of CBZ for a minimum of 14 days prior to Day -28. No change in baseline AEDs are expected during the treatment period.~* The patient must be able to comply with maintaining an accurate epilepsy medication dosing diary and seizure diary.~* If female: Patient is not of childbearing potential.~* If childbearing potential: Must have a negative serum pregnancy test at Day -28 and a negative serum pregnancy test on Day -1; Must comply with a method of birth control acceptable to the investigator (with the exception of hormone based contraceptives which are contraindicated with the use of CBZ).~Exclusion Criteria:~* Patient is taking a daily oral dose of CBZ greater than 2000 mg per day.~* Patient is being treated with hormone based therapy for birth control.~* Patient has a QTc interval value that is greater than 450 msec.~* Patient has a screening ALT, AST or bilirubin \> 3 times the upper limit of normal.~* Patients with CLCR \< 30 mL/min or with a renal disorder (i.e. nephrotic syndrome, patients on hemodialysis or peritoneal dialysis or being considered for peritoneal or hemodialysis).~* Patient is receiving oral CBZ for absence seizures.~* Patient has had an episode of status epilepticus within 30 days of screening.~* Patient has a history of severe or serious adverse reactions to CBZ (e.g. aplastic anemia, agranulocytosis).~* Patient has been diagnosed with narrow angle glaucoma.~* Patient weighs less than 50 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).